HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Liang Chen Selected Research

cheliensisin A

2/2014Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells.
9/2013Cheliensisin A inhibits EGF-induced cell transformation with stabilization of p53 protein via a hydrogen peroxide/Chk1-dependent axis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Liang Chen Research Topics

Disease

69Neoplasms (Cancer)
01/2016 - 07/2003
21Infection
05/2015 - 01/2008
18Lung Neoplasms (Lung Cancer)
05/2015 - 03/2002
14Pain (Aches)
07/2015 - 11/2004
12Compression Fractures (Compression Fracture)
01/2013 - 11/2004
10Breast Neoplasms (Breast Cancer)
02/2016 - 01/2011
9Inflammation
10/2015 - 01/2010
9Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2015 - 05/2007
8Osteosarcoma (Osteogenic Sarcoma)
09/2015 - 01/2009
8Wounds and Injuries (Trauma)
02/2015 - 09/2005
6Neoplasm Metastasis (Metastasis)
02/2016 - 06/2011
6Pancreatic Neoplasms (Pancreatic Cancer)
10/2015 - 01/2014
6Atherosclerosis
03/2015 - 10/2004
6Body Weight (Weight, Body)
10/2014 - 09/2005
5Anoxia (Hypoxia)
11/2015 - 06/2004
4Colonic Neoplasms (Colon Cancer)
08/2015 - 06/2005
4Paralysis (Palsy)
07/2015 - 05/2002
4Atherosclerotic Plaque (Atheroma)
03/2015 - 04/2007
4Cardiovascular Diseases (Cardiovascular Disease)
02/2015 - 05/2009
4Fibrosis (Cirrhosis)
12/2014 - 08/2010
4Hepatocellular Carcinoma (Hepatoma)
12/2014 - 06/2011
4Cicatrix (Scar)
10/2014 - 04/2006
4Chronic Hepatitis B
01/2014 - 09/2011
4Atrial Fibrillation
10/2013 - 08/2010
4Osteolysis
04/2013 - 08/2011
3Lung Diseases (Lung Disease)
08/2015 - 09/2011
3Endocarditis
05/2015 - 12/2011
3Hypertension (High Blood Pressure)
05/2015 - 05/2009
3Human Influenza (Influenza)
01/2015 - 01/2005
3Fistula
01/2015 - 05/2007
3Septic Shock (Toxic Shock Syndrome)
01/2015 - 08/2013
3Heart Failure
01/2015 - 08/2010
3Myocardial Infarction
01/2015 - 09/2010
3Hepatitis B
12/2014 - 01/2014
3Spinal Cord Injuries (Spinal Cord Injury)
10/2014 - 08/2013
3Insulin Resistance
08/2014 - 01/2010
3Liver Diseases (Liver Disease)
01/2014 - 01/2011
3Hypertrophic Cicatrix (Hypertrophic Scar)
09/2013 - 06/2006
3Aneurysm (Aneurysms)
08/2013 - 02/2012
3Kyphosis
07/2013 - 05/2007
3Ischemia
12/2007 - 06/2004
2Cardiomyopathies (Cardiomyopathy)
02/2016 - 01/2013
2Neuralgia (Stump Neuralgia)
12/2015 - 01/2015
2Cardiomegaly (Heart Hypertrophy)
12/2015 - 05/2009

Drug/Important Bio-Agent (IBA)

16Biological Markers (Surrogate Marker)IBA
10/2015 - 11/2007
14MicroRNAs (MicroRNA)IBA
12/2015 - 01/2011
13Proteins (Proteins, Gene)IBA
01/2016 - 01/2009
10Messenger RNA (mRNA)IBA
08/2015 - 01/2008
8Phosphotransferases (Kinase)IBA
02/2014 - 06/2006
6DNA (Deoxyribonucleic Acid)IBA
08/2015 - 01/2005
6AntigensIBA
01/2015 - 03/2002
6Carbon MonoxideIBA
03/2014 - 05/2002
5RNA (Ribonucleic Acid)IBA
08/2015 - 05/2007
5CollagenIBA
05/2015 - 06/2008
4entecavirFDA Link
04/2015 - 09/2011
4AdiponectinIBA
03/2015 - 04/2007
4Alanine Transaminase (SGPT)IBA
01/2015 - 12/2011
4CytokinesIBA
01/2015 - 01/2010
4Glucose (Dextrose)FDA LinkGeneric
08/2014 - 05/2007
4Epidermal Growth Factor Receptor (EGF Receptor)IBA
11/2013 - 06/2006
4CalciumIBA
12/2012 - 06/2006
4Sirolimus (Rapamycin)FDA Link
07/2010 - 07/2007
3Doxorubicin (Adriamycin)FDA LinkGeneric
02/2016 - 07/2006
3Glutathione (Reduced Glutathione)IBA
11/2015 - 12/2010
3N- (4- (3- chloro- 4- (2- pyridinylmethoxy)anilino)- 3- cyano- 7- ethoxy- 6- quinolyl)- 4- (dimethylamino)- 2- butenamideIBA
10/2015 - 06/2006
3DaptomycinFDA Link
08/2015 - 11/2012
3Protein Kinases (Protein Kinase)IBA
05/2015 - 05/2007
3resveratrolIBA
05/2015 - 01/2014
3Lamivudine (3TC)FDA Link
04/2015 - 09/2011
3polylactic acid-polyglycolic acid copolymer (PLGA)IBA
02/2015 - 07/2010
3Interleukin-6 (Interleukin 6)IBA
01/2015 - 02/2010
3Advanced Glycosylation End ProductsIBA
01/2015 - 01/2012
3NF-kappa B (NF-kB)IBA
09/2014 - 05/2009
3InterferonsIBA
08/2014 - 01/2012
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2014 - 01/2012
3TitaniumIBA
07/2013 - 04/2006
3Small Interfering RNA (siRNA)IBA
01/2013 - 01/2010
3Heat-Shock Proteins (Heat-Shock Protein)IBA
12/2012 - 09/2011
3AMP-Activated Protein KinasesIBA
01/2011 - 01/2008
3PPAR gammaIBA
04/2010 - 10/2008
3erlotinib (CP 358,774)FDA Link
01/2009 - 06/2006
3OxygenIBA
10/2008 - 05/2007
2Serotonin (5 Hydroxytryptamine)IBA
02/2016 - 01/2015
2NanoGelIBA
01/2016 - 06/2014
2polymethacrylic acid (PMAA)IBA
01/2016 - 06/2014
2Superoxide DismutaseIBA
11/2015 - 08/2015
2Acid PhosphataseIBA
11/2015 - 08/2015
2CopperIBA
11/2015 - 08/2015
2ZincIBA
11/2015 - 08/2015

Therapy/Procedure

18Kyphoplasty
07/2015 - 11/2004
16Heterologous Transplantation (Xenotransplantation)
10/2015 - 01/2009
9Drug Therapy (Chemotherapy)
12/2015 - 03/2011
9Vertebroplasty
07/2015 - 07/2007
6Chinese Traditional Medicine (Traditional Chinese Medicine)
10/2015 - 01/2012
5Decompression
01/2015 - 12/2010
4Craniotomy
01/2015 - 07/2003
3Therapeutics
07/2015 - 01/2010
3Stents
12/2014 - 03/2009
3Artificial Respiration (Mechanical Ventilation)
07/2011 - 02/2007
3Aftercare (After-Treatment)
04/2011 - 09/2010